
Severe Acne Vulgaris - Pipeline Insight, 2025
Description
DelveInsight’s, “Severe Acne Vulgaris - Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Acne Vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Severe Acne Vulgaris: Overview
Acne vulgaris (commonly referred to as acne) is a common skin disease in which hair follicles become clogged with dead skin and oils resulting in inflammation. Acne has a varied etiology which includes genetics, hormonal function, bacterial growth, and other causes. Clinically, ance can be identified by open or closed comedones, and/or by erythematous papules and pustules on the face, as well as erythema on the surrounding skin. Likewise, acneiform scarring may also occur which may or may not present with comedones. The diagnosis of acne is based on the history and physical examination. Lesions most commonly develop in areas with the greatest concentration of sebaceous glands, which include the face, neck, chest, upper arms, and back. Acne may be triggered or worsened by external factors such as mechanical obstruction (i.e., helmets, shirt collars), occupational exposures, or medications. Common medications that may cause or affect acne are listed in Table 1.4 Cosmetics and emollients may occlude follicles and cause an acneiform eruption. Topical corticosteroids may produce perioral dermatitis, a localized erythematous papular or pustular eruption.
""Severe Acne Vulgaris - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Severe Acne Vulgaris pipeline landscape is provided which includes the disease overview and Severe Acne Vulgaris treatment guidelines. The assessment part of the report embraces, in depth Severe Acne Vulgaris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Severe Acne Vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Severe Acne Vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Severe Acne Vulgaris Emerging Drugs
Further product details are provided in the report……..
Severe Acne Vulgaris: Therapeutic Assessment
This segment of the report provides insights about the different Severe Acne Vulgaris drugs segregated based on following parameters that define the scope of the report, such as:
Severe Acne Vulgaris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Severe Acne Vulgaris therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Severe Acne Vulgaris drugs.
Severe Acne Vulgaris Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Severe Acne Vulgaris: Overview
Acne vulgaris (commonly referred to as acne) is a common skin disease in which hair follicles become clogged with dead skin and oils resulting in inflammation. Acne has a varied etiology which includes genetics, hormonal function, bacterial growth, and other causes. Clinically, ance can be identified by open or closed comedones, and/or by erythematous papules and pustules on the face, as well as erythema on the surrounding skin. Likewise, acneiform scarring may also occur which may or may not present with comedones. The diagnosis of acne is based on the history and physical examination. Lesions most commonly develop in areas with the greatest concentration of sebaceous glands, which include the face, neck, chest, upper arms, and back. Acne may be triggered or worsened by external factors such as mechanical obstruction (i.e., helmets, shirt collars), occupational exposures, or medications. Common medications that may cause or affect acne are listed in Table 1.4 Cosmetics and emollients may occlude follicles and cause an acneiform eruption. Topical corticosteroids may produce perioral dermatitis, a localized erythematous papular or pustular eruption.
""Severe Acne Vulgaris - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Severe Acne Vulgaris pipeline landscape is provided which includes the disease overview and Severe Acne Vulgaris treatment guidelines. The assessment part of the report embraces, in depth Severe Acne Vulgaris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Severe Acne Vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Severe Acne Vulgaris.
- In the coming years, the Severe Acne Vulgaris market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Severe Acne Vulgaris R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Severe Acne Vulgaris treatment market. Several potential therapies for Severe Acne Vulgaris are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Severe Acne Vulgaris market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Severe Acne Vulgaris) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
This segment of the Severe Acne Vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Severe Acne Vulgaris Emerging Drugs
- ASC40: Ascletis Pharmaceuticals
- BPX-01: BIOPHARMX
Further product details are provided in the report……..
Severe Acne Vulgaris: Therapeutic Assessment
This segment of the report provides insights about the different Severe Acne Vulgaris drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Severe Acne Vulgaris
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Severe Acne Vulgaris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Severe Acne Vulgaris therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Severe Acne Vulgaris drugs.
Severe Acne Vulgaris Report Insights
- Severe Acne Vulgaris Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Severe Acne Vulgaris drugs?
- How many Severe Acne Vulgaris drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Severe Acne Vulgaris?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Severe Acne Vulgaris therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Severe Acne Vulgaris and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ascletis Pharmaceuticals
- BioPharmX Corporation
- Biofrontera
- Boston Pharmaceuticals
- Botanix Pharmaceuticals
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Vyne Therapeutics Inc.
- DERMATA THERAPEUTICS
- Novan
- ASC40
- BPX-01
- BF-200
- BOS-356
- BTX 1503
- Aminolevulinic acid
- FCD105
- DMT310
- VB-1953
- SB 204
Table of Contents
70 Pages
- Introduction
- Executive Summary
- Severe Acne Vulgaris: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Severe Acne Vulgaris – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- BPX-01: BIOPHARMX
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Severe Acne Vulgaris Key Companies
- Severe Acne Vulgaris Key Products
- Severe Acne Vulgaris- Unmet Needs
- Severe Acne Vulgaris- Market Drivers and Barriers
- Severe Acne Vulgaris- Future Perspectives and Conclusion
- Severe Acne Vulgaris Analyst Views
- Severe Acne Vulgaris Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.